EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

An Epstein‐Barr Virus Nuclear Antigen 1 (EBNA1) Serology Test Strip for Nasopharyngeal Carcinoma Risk Screening

Benjamin E Warner iD, Japan Patel iD, Rebecca Satterwhite iD, Renwei Wang iD, Jennifer Adams-Haduch iD, Woon-Puay Koh iD, Jian-Min Yuan iD, Kathy H Y Shair iD

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.71082 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Benjamin E Warner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Epstein-Barr Virus Nuclear Antigens, Nasopharyngeal Neoplasms, Antibodies, Viral, Epstein-Barr Virus Infections. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hillman Foundation, NCI NIH HHS, Singapore Strategic Cohorts Consortium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies to Epstein‐Barr virus (EBV) proteins can predict nasopharyngeal carcinoma (NPC) risk. We previously defined a prototype EBNA1 protein panel and multiplex immunoblot assay that distinguishes NPC risk several years pre‐diagnosis. Assay throughput and specificity are critical to effectively implement a population‐level screening program. Here, we developed a strip test assay—EBNA1 SeroStrip‐HT—with an objective to increase throughput and maximize specificity. EBNA1 full‐length (FL) and glycine‐alanine repeat deletion mutants (dGAr) were purified from insect and mammalian cells to screen serum IgA/IgG from prospective cohorts in Singapore and Shanghai, China, with known time intervals to NPC diagnosis. Twenty pre‐diagnostic sera within 4 years to diagnosis were compared to 96 healthy controls using a nested case‐control study design. IgA to mammalian‐derived EBNA1 dGAr achieved 85.0% sensitivity and 94.8% specificity (AUC, 0.939) for NPC status. IgA to insect‐derived EBNA1 dGAr showed the same sensitivity (85.0%) and similar specificity (93.8%) (AUC, 0.941). IgA to insect‐derived EBNA1 FL had a higher 90% sensitivity, but lower 91.7% specificity (AUC, 0.940). Combining EBNA1 FL and dGAr results showed that subjects positive for both proteins had a 243.67 odds ratio for NPC incidence compared to double‐negative scores. This study demonstrated the efficacy of EBNA1 SeroStrip‐HT for NPC risk assessment and stratification in high‐ and intermediate‐risk populations, yielding high accuracy and a 12‐fold increased throughput over the prototype. The insect system was appropriate for large‐scale production of purified EBNA1. Larger, geographically diverse cohorts are warranted to confirm these results, especially in low‐incidence populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus Nuclear AntigensNasopharyngeal NeoplasmsAntibodies, ViralEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansSensitivity and SpecificityChinaImmunoglobulin ACarcinomaNasopharyngeal CarcinomaImmunoglobulin GSingaporeSerologic TestsAnimalsFemaleCase-Control StudiesProspective Studies

Substanzen

Epstein-Barr Virus Nuclear AntigensEBV-encoded nuclear antigen 1Antibodies, ViralImmunoglobulin AImmunoglobulin G

Autor:innen und Institutionen

  • Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Cancer Epidemiology and Prevention Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Cancer Risk, Outcomes and Prevention Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

ORCID-Profile: Benjamin E Warner, Japan Patel, Rebecca Satterwhite, Renwei Wang, Jennifer Adams-Haduch, Woon-Puay Koh, Jian-Min Yuan, Kathy H Y Shair

Förderung

  • Hillman Foundation
  • NCI NIH HHS
  • Singapore Strategic Cohorts Consortium
  • NIDCR NIH HHS
  • NIH HHS

Zitieren

APA

Warner, B. E., Patel, J., Satterwhite, R., Wang, R., Adams-Haduch, J., Koh, W. P., Yuan, J. M., & Shair, K. H. Y. (2026). An Epstein‐Barr Virus Nuclear Antigen 1 (EBNA1) Serology Test Strip for Nasopharyngeal Carcinoma Risk Screening. Journal of Medical Virology. https://doi.org/10.1002/jmv.71082

Vancouver

Warner BE, Patel J, Satterwhite R, Wang R, Adams-Haduch J, Koh WP, et al. An Epstein‐Barr Virus Nuclear Antigen 1 (EBNA1) Serology Test Strip for Nasopharyngeal Carcinoma Risk Screening. Journal of Medical Virology. 2026. doi:10.1002/jmv.71082

BibTeX
@article{Warner2026,
  author = {Warner, Benjamin E and Patel, Japan and Satterwhite, Rebecca and Wang, Renwei and Adams-Haduch, Jennifer and Koh, Woon-Puay and Yuan, Jian-Min and Shair, Kathy H Y},
  title = {An Epstein‐Barr Virus Nuclear Antigen 1 (EBNA1) Serology Test Strip for Nasopharyngeal Carcinoma Risk Screening},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.71082}
}
Kostenlos starten →